XNASALLK
Market cap108mUSD
Dec 31, Last price
1.21USD
1D
1.68%
1Q
89.09%
IPO
-96.55%
Name
Allakos Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
34.35%
Rev. gr., 5y
1.64%
Revenues
0k
Net income
-186m
L-41.51%
CFO
-116m
L-58.40%
Earnings
Mar 12, 2025
Profile
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 202,197 | 332,404 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (202,197) | (332,404) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (2,477) | |||||||
Tax Rate | ||||||||
NOPAT | (202,197) | (329,927) | ||||||
Net income | (185,701) -41.51% | (317,475) 18.83% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 990 | 140,591 | ||||||
BB yield | -0.42% | -26.38% | ||||||
| Debt | ||||||||
Debt current | 3,250 | 3,161 | ||||||
Long-term debt | 76,430 | 91,898 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (91,114) | (186,199) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (116,480) | (279,971) | ||||||
CAPEX | (592) | (8,333) | ||||||
Cash from investing activities | 93,175 | 71,681 | ||||||
Cash from financing activities | 2,528 | 141,882 | ||||||
FCF | (188,153) | (326,669) | ||||||
| Balance | ||||||||
Cash | 170,794 | 279,786 | ||||||
Long term investments | 1,472 | |||||||
Excess cash | 170,794 | 281,258 | ||||||
Stockholders' equity | (1,118,339) | (932,975) | ||||||
Invested Capital | 1,328,621 | 1,292,518 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 86,798 | 63,284 | ||||||
Price | 2.73 -67.58% | 8.42 -13.99% | ||||||
Market cap | 236,959 -55.53% | 532,851 1.11% | ||||||
EV | 145,845 | 346,652 | ||||||
EBITDA | (196,056) | (325,333) | ||||||
EV/EBITDA | ||||||||
Interest | 3,673 | |||||||
Interest/NOPBT | ||||||||